Gove R I, Burge P S, Stableforth D E, Skinner C
Department of Thoracic Medicine, East Birmingham Hospital, Bordesley Green East, UK.
Eur J Clin Pharmacol. 1988;34(6):585-9. doi: 10.1007/BF00615221.
In order to examine a possible mechanism of action of ketotifen in asthma, a double-blind study was undertaken to determine whether ketotifen showed any effects on the beta-adrenergic system in asthmatic patients. The effects of ketotifen 1 mg b.i.d. for one month on the changes in spirometry, plasma potassium and serum glucose nebulized salbutamol was compared with placebo. In addition the degree of inhibition caused by local salbutamol on the wheal volume due to intradermal prostaglandin E and bradykinin, was compared following ketotifen and placebo. Nebulized salbutamol produced consistent improvements in spirometry and changes in potassium and glucose levels. Local salbutamol significantly decreased the wheal volume induced by intradermal prostaglandin E and bradykinin. However, none of these salbutamol-induced effects were altered following ketotifen or placebo. Ketotifen, in the doses used, has no demonstrable effect on the beta-adrenergic system in asthmatic patients.
为研究酮替芬在哮喘中的可能作用机制，进行了一项双盲研究，以确定酮替芬对哮喘患者的β-肾上腺素能系统是否有任何影响。将酮替芬1毫克每日两次服用一个月对肺功能测定、血浆钾和血清葡萄糖的变化以及雾化沙丁胺醇的影响与安慰剂进行比较。此外，在服用酮替芬和安慰剂后，比较局部沙丁胺醇对皮内前列腺素E和缓激肽引起的风团体积的抑制程度。雾化沙丁胺醇在肺功能测定以及钾和葡萄糖水平变化方面产生了持续改善。局部沙丁胺醇显著降低了皮内前列腺素E和缓激肽诱导的风团体积。然而，这些沙丁胺醇诱导的效应在服用酮替芬或安慰剂后均未改变。所用剂量的酮替芬对哮喘患者的β-肾上腺素能系统没有明显作用。
